Background: The non-linear mixed amount with zero amounts response surface model can be used to describe drug interactions and predict loss of response to noxious stimuli and respiratory depression. We aimed to determine whether this response surface model could be used to model sedation with the triple drug combination of midazolam, alfentanil and propofol. Methods: Sedation was monitored in 56 patients undergoing gastrointestinal endoscopy (modelling group) using modified alertness/sedation scores. A total of 227 combinations of effect-site concentrations were derived from pharmacokinetic models. Accuracy and the area under the receiver operating characteristic curve were calculated. Accuracy was defined as an absolute difference <0.5 between the binary patient responses and the predicted probability of loss of responsiveness. Validation was performed with a separate group (validation group) of 47 patients. Results: Effect-site concentration ranged from 0 to 108 ng ml À1 for midazolam, 0e156 ng ml À1 for alfentanil, and
Editor's key points
Combinations of two or more drugs, commonly used for sedation, result in complex interactions. In contrast with two drug combinations, little progress has been made with modelling triple drug interactions. The authors studied interactions among alfentanil, midazolam, and propofol using a non-linear mixed amount with zero amounts model. This model was able to predict loss of responsiveness and respiratory depression with reasonable accuracy.
Effective sedation aims to make patients comfort while minimising adverse effects such as respiratory depression (RD). Drugs that treat anxiety, pain, and awareness are usually given in combination to make patients comfortable during invasive procedures. This can increase the risk of adverse events such as RD or slow the workflow through sites of care that require rapid patient turnover.
Response surface models (RSMs) predict drug response by integrating isobolographic data with concentration effect curves and curve shift effects. 1e5 These models work well for dual drug combinations such as combinations of inhalation agents, i.v. hypnotics, opioids, a 2 -agonists, or non-steroidal anti-inflammatory drugs. However, triple drug interactions are difficult to study because of the complex model development process needed to describe all drug combinations.
Triple drug models have been developed for anticancer or antifungal therapy based on in vitro microbial kill rates. Anaesthesia models differ by using patient response as an end measure. 2, 13 Triple drug interaction models have been developed using hierarchy and non-RSMs, including doublesedative-single-opioid and sedative-opioid-volatile agent combinations. 13, 14 However, practical clinical use of this approach is limited because these studies used drug doses calculated in milligrams per kilograms. It is difficult to translate this type of dose calculation into clinical practice where drugs are often given in multiple boluses and at varying intervals.
Our aim was to design and describe a new anaesthetic interaction model predicting patient response during sedation that could be adapted for practical use. We chose the nonlinear mixed amount with zero amount (NLMAZ) as a response surface approach for model development, because it allows independent flexibility expressed as functions in all of the Hill's parameters. 15 These functions can capture local differences in synergism, additivity, or antagonism in a single data set. We hypothesise that an integrated model from upper and lower endoscopy sedation also adequately describes responses in a separate group of patients. A secondary aim was to use our model design to improve sedation safety by predicting the risk of RD. We anticipate that this type of model could have practical clinical application and warrants further evaluation.
Methods

Study group
This was a single-centre observational study. Institutional Review Board approval at the Taipei Veterans General Hospital was obtained before recruitment (IRB number: 2016-04-003C and 2017-03-003B). Written informed consent was obtained from all subjects. ASA (class 1 or 2) patients aged between 20 and 80 yr scheduled for oesophagogastroduodenoscopy (OGD) or colonoscopy were candidates for the study. Our estimated sample size was 60 patients. A previous study 16 showed an efficient criss-cross design requiring 20 patients, while the radial and slice design required 40 patients to define a reliable dual-drug response surface. Our study manifested non-steady state drug concentrations and the drug administration shared similarities with the radial design.
Patients were excluded if they had documented impairment in verbal communication, history of facial or neck surgery, pre-examination SpO 2 <95%, or a history of sedative, opioid, or chronic alcohol use. Two groups of patients were enrolled: a modelling group to construct the RSM, which included both upper (OGD) and lower (colonoscopy) endoscopy; and a validation group. The latter sample only received upper endoscopy and was used to evaluate the model's clinical applicability.
Anaesthesia management
Anaesthetic drugs were given through a 22-gauge i.v. catheter placed in a distal arm. Patients were monitored using standard non-invasive equipment: electrocardiography, pulse oximetry, and non-invasive blood pressure. Supplemental oxygen was administered by nasal cannula at 5 L min
À1
. One anaesthesiologist in each session administered bolus i.v. doses of midazolam, alfentanil, or propofol based on clinical preferences.
The Modified Observer Assessment of Alertness/Score (MOAA/S) 17, 18 was used to measure arousal by clinical observation on a 0e5 scale where 5 was awake and 0 was unresponsive to noxious stimuli. Endoscopy began when the patient reached loss of response (LOR), defined by MOAA/S<2 (no response to prodding or noxious stimuli). Additional alfentanil was given if the patient appeared uncomfortable. Midazolam or propofol was given if the patient's MOAA/S was >4 with or without pain. After each bolus, the medication was flushed with 3 ml of normal saline. RD was defined as severe hypoxaemia shown by a reliable pulse oximetry reading <90%, regardless of the duration. Two health care providers trained in MOAA/S scored depth of sedation at the start and the end of the examination, or at critical events (occurrence of RD, endoscope insertion, painful expression) for each study patient. Loss of response was defined as MOAA/S<2. We pooled upper and lower endoscopy into one single session based on previous findings showing a similar pain intensity. 19 
Pharmacodynamic response surface model
We use the NLMAZ model as our response surface model. It is an extension to the mixed amount with zero amount observation model and was first proposed by White and colleagues. 15 The original form is as follows:
where E is the effect, defined as the probability of LOR. E max is the maximal drug effect possible and E 0 is the baseline probability when no drugs are present. U 50 is the value of U resulting in 50% of the maximal effect, that is, to achieve 50% chance of LOR. U resembles that in the Minto model, which can be interpreted as a new drug and is the sum of the normalised potency of midazolam, alfentanil, and propofol [equations (2) and (3)]:
The variables C m , C a and C p refer to the calculated Ce of midazolam, alfentanil, and propofol, respectively. For consistency throughout the article, the subscripts m, a, and p will refer as midazolam, alfentanil, and propofol, respectively. C 50 is defined as the concentration of drug required to provide half maximal effect. For the model to scale correctly, we have to define:
where x, y, and z are the drug fractions of midazolam, alfentanil, and propofol. Our data were categorical and the final equation was modified. We divided the data into binary responses, which gave further assumption that E max should be 1 (LOR) and E 0 should 0 (no LOR), and this reduced the equation to:
The unknown parameters (P) are defined using the full cubic form of the canonical polynomial, as in equation (7):
This can be expanded into:
The Greek letter constants are referred to as the vector constants. Equation (8) is a generalised form of the parameters n and U 50 , where they substitute P and each has their designated vector constants:
n ¼ a n;m x þ a n;a y þ a n;p z þ b n;ma xy þ b n;mp xz þ b n;ap yz þ g n;ma xyðx À yÞ þ g n;mp xzðx À zÞ þ g n;ap yzðy À zÞ þ d n;map xyz
Using log 10 forces the value of U 50 to unity. The leading factor (1ex)(1ey)(1ez) creates zero for log 10 U 50 , or U 50 ¼1 at the vertices of the ternary plot. This process is used to fit the ternary plot correctly, where the value of the U 50 vertical axis is between 0 and 1.
Each constant defined a specific region of the interaction surface and thus this allows the model to capture different degrees of interaction at different drug ratios. The final NLMAZ model will have 23 parameters obtained from the iteration process. This included 20 vector parameters (a n,m , a n,a , a n,p , b n,ma , b n,mp , b n,ap , g n,ma , g n,mp , g n,ap , d n,map , a U,m , a U,a , a U,p , b U,ma , b U,mp , b U,ap , g U,ma , g U,mp , g U,ap , d U,map ) and three C 50 (C 50m , C 50a , C 50p ) parameters. All of the data sets in the modelling group are pooled for parameter estimation.
U 50 will bow downward if the drug interaction is synergistic, resulting in an increase in E [equation (5)]. The interaction is antagonistic if the surface takes the shape of a dome. U is identical to U 50 if we look at a fixed effect endpoint where E¼0.5. For consistency, U 50 will be used throughout the article. We use an accepted definition of additivity when 0.9<U 50 <1.1. 20 The unit of the axis is drug fraction rather than drug concentration. Each point in the plot corresponds to a specific drug ratio with each sum equal to 1.
Pharmacokinetic modelling
Pharmacokinetic profiles for effect-site drug concentrations (Ce) were calculated using a simulation program (TIVA trainerVersion 9.1, Build 5, Euro SIVA, Netherlands 
Effect measure modelling and fit assessment
The model was fit to propofol, alfentanil, and midazolam effect-site concentrations and LOR absence or presence during endoscopy procedures. Model parameters were estimated with Matlab software (R2017b, The MathWorks, Inc., Natick, MA, USA) for pharmacodynamic analysis. Matlab's built-in function, fmincon(), was selected, and an iterative process (2000 iterations) utilising the bootstrap method 26e28 was used to find the minimum value of e2 times the logarithm of the maximum likelihood (e2LL) in equation (11) .
K was the number of pooled observations. Ri is the response to stimuli measured by MOAA/S (Ri ¼ 0 for score 1 or 0, Ri ¼ 1 for score 2 or higher). Pi, the probability for LOR to stimuli was calculated from the model. The relative standard errors (RSE) of the model parameters were calculated by dividing the standard error by the estimated parameter value.
Accuracy was defined as an absolute difference <0.5 between the binary patient responses and the predicted probability of LOR. The discriminating power of the model in both patient groups was measured using receiver operating characteristic (ROC) curves. ROC curve input was the observed and model predicted responses in both patient groups. Areas under the curves (AUCs) and 95% confidence intervals were calculated to assess the performance of the RSM objectively.
Respiratory depression analysis
RD events were analysed separately after response surface model construction. The calculated concentrations were transformed into individual fractions. RD concentration pairs were then plotted on a three-dimensional scatter plot and a boundary for RD was graphed.
Results
Patient characteristics and pharmacokinetic data
In the modelling group, a total of 56 Taiwanese patients were enrolled, with 59% (n¼33) being female. Four patients were excluded for inadequate sedation documentation. Mean (standard deviation) age and BMI were 53.3 (13.3) yr and 23.1 (3.7) kg m
À2
, respectively while average body weight was 61.6 (13.1) kg. There were 227 concentration sets for pooling and model construction.
There were no significant differences between the patient characteristics of the modelling group and the 47 Taiwanese patients enrolled into the validation group. The validation sample was 68% (n¼32) female with an average age of 49.3 (13.5) yr, and average BMI and body weight of 23.7 (3.9) kg m À2 and 62.9 (13.0) kg, respectively. There were 188 data sets available for validation. The concentration in both groups ranged from 0 to 108 ng ml À1 for midazolam, 0e156 ng ml À1 for alfentanil and 0e2.6 mg ml À1 for propofol.
The minimum number of recordings per patient was two: one at the start where instrumentation was performed and one at the end of the procedure when there was an observed return of consciousness. Most patients required additional drug boluses during the examinations to manage discomfort. This produced an average of four recordings per patient. Modelling concentrations above the estimated C 50 were 24%, 0%, and 4% for midazolam, alfentanil, and propofol, respectively.
Response surface
The parameters are listed in Table 1 . The parameters b U,ma , b U,mp , and b U,ap shaped the concavity of the surface on the axes border where a negative value produces downward bowing. The b values were used to gauge and compare interactions between drug pairs. U 50 decreased as b decreased. b U,ma has the lowest value (b U,ma ¼À0.99) among the three, and hence, synergy was strongest between midazolam and alfentanil.
The complete form of NLMAZ model is a four-dimensional graph and precludes direct plotting. We graphed the U 50 surface ternary plot to illustrate the degree of interaction between the three drugs (Fig. 1) . The graph is scaled from 0 to 1 in the zaxis. Each vertex represents the presence of only a single drug where the single drug fraction is equal to 1. For example, the vertex between midazolam and alfentanil represents midazolam fraction of 1, suggesting midazolam as the sole drug at this point.
The U 50 surface and the axes showed a trend toward downward bowing, indicating synergism between the pairwise and three-drug combinations. Interaction between midazolam and alfentanil was the strongest of the pairs, as shown by the skewing of the nadir toward the midazolamealfentanil side.
The RSE is 171% for the parameter g n,ma ( Table 1) . Impact of this single parameter was trivial. The results were negligible after test graphing with g n,ma in the range of À100 to 100, which was much greater than the current value.
The triple interaction term d U;map was À0.31, indicating that additional synergy is modest when the three drugs are given simultaneously. The minimal U 50 is 0.74 when the ratio between midazolam, alfentanil, and propofol is 0.35, 0.37, and 0.28. Figure 2 shows the concentration effect curve with patient concentration sets at different fractions of the drugs. The majority of alfentanil fractions are at or below 0.1 and therefore it is fixed at 0.1 for this figure. It was difficult to fix a predefined drug fraction in actual practice. The red dots are the concentration sets that allowed less than 10% error for the defined fraction of all drugs given simultaneously. The dotted red line indicates the concentration for midazolam and propofol when LOR probability is 50%. This line separates the concentrations sets well into binary responses and is used to defined accuracy for model fit. The accuracy was 83% and 76% for the modelling and validation group, respectively.
In Figure 3 , concentrationeeffect curves compare the drug fractions that are outside the normal clinical range for single or dual drugs. The alfentanil-only curve is not displayed because opioids do not produce reliable hypnosis. As the midazolam fraction decreases, the curves become steeper. At same midazolam fractions, we can see the decrease in the concentration required for midazolam to achieve 50% LOR is lower if paired with alfentanil. The interaction between the three drugs administered simultaneously is shown in Figure 4 . Each panel shows how the interaction changed between two drugs when the third drug's concentration increased by 10% of its C 50 . The solid black lines are the 50% isoboles and the dashed red line represented the line of additivity.
The degree of synergy (bowing of the isoboles toward the origin) is greater when the third drug's concentration is lower. The dotted blue line connects the point of strongest synergy, hence the lowest U 50 , of different isoboles. This line deviates toward the drug that has a stronger synergy with the third drug. A detailed analysis to identify the threshold from synergy to additivity among the 50% isoboles was performed by plotting the isoboles across all drug concentrations and combinations. U 50 was our threshold value. This identified the fraction for each drug to maintain synergism with the other two drugs at 0.85, 0.85, and 0.8 for midazolam, alfentanil, and propofol, respectively. The corresponding Ce values at specified threshold fraction were approximately 76%, 76%, and 72% of C 50 for midazolam, alfentanil, and propofol, respectively.
In Figure 4A , propofolealfentanil interaction is stronger than propofolemidazolam. The lowest U 50 is 0.77 when the range of alfentanil fraction was <0.12 or alfentanil concentration was <125 ng ml
À1
. This occurred near the 20% alfentanil isobole in Figure 4C . The lowest U 50 within the acceptable alfentanil range is 0.82 in Figure 4A and 0.87 in Figure 4B .
The ROC curves are displayed in Figure 5 . The AUC of the modelling and validation group were 0.87 and 0.80, respectively. The 95% confidence interval is above the identity line for both groups (Table 1 ). This indicated that the model performed well in both groups, with strong discriminating power.
Respiratory depression
Two patients (3%) in the modelling group experienced RD during sedation. Both cases were managed with the placement of a nasal airway and manual mask ventilation. The hypoxic events lasted <1 min. Heart rate, blood pressure, and continuous electrocardiography readings were normal. Both patients recovered uneventfully. There were no hypoxic events in the validation group.
The alfentanil fraction was below 0.12 for 90% of the concentrations in the modelling group. Five patients (9%) had alfentanil fraction above 0.12. A flat surface represented alfentanil fraction fixed at 0.12 and its relationship to midazolam and propofol (Fig. 6) . Concentration sets were scattered on the plot with red circles below the surface and blue above. Surface region in grey colour indicated LOR probability >0.5. RD events were marked by filled circles (2% of all data sets). These events were always above the alfentanil fraction 0.12 threshold and with a LOR probability <0.5. None of the concentration pairs in the validation group exceeded the alfentanil fraction 0.12 threshold.
Discussion
This is the first application of the NLMAZ model evaluating the clinical response of three anaesthetics. Our model has . U 50 value <1 indicates some degree of synergy. An additive interaction will result in a flat surface, while antagonism will take the shape of a dome. A shaded area highlights the region where alfentanil fraction is <0.12, which covers the majority of the recorded concentrations in this study.
practical implications for clinical care. The model performed well under clinical conditions. It was 76e83% accurate in predicting LOR for combinations of midazolam, alfentanil, and propofol during endoscopic sedation and RD risk could be estimated.
Investigators have used various designs to describe the few studies on triple drug interactions. The new C 50r , g 0 , and g were linearly interpolated from the original parameters in a single study. 26 This was different from our approach where n and log 10 U 50 were cubic polynomial functions. Interactions between midazolam, alfentanil, and propofol have also been performed using logit and probit curves. 13 The log(dose)e response curves were linear and can be extended to three-drug model from the original two-drug design. 29 Another study investigated the interaction between nitrous oxide, sevoflurane, and fentanyl by assuming nitrous oxide altered the C 50 of either sevoflurane or fentanyl. 30 It was a simple extension of the hierarchy model and also assumes uniform interaction across the surface. The most recognised triple model was developed by Minto and colleagues. 2 In this model, the parameters were described by a quadratic polynomial equation. Drug concentrations are represented by their fractional combination in the mixture. The Minto and NLMAZ models share a similar feature of incorporated interaction functions to describe the parameters, but the NLMAZ model had more parameters. Even though Minto and colleagues 2 used a different mathematical model, data presentation is similar to our NLMAZ model. The U 50 for drug combinations, a dimensionless value of the mixture of midazolam, alfentanil, and propofol is used in both models to gauge the type and degree of interaction between the drugs (Fig. 1) . Synergy is greater as the value of U 50 decreases. We identified three types of drug interactions to help guide the choice or dosing of medications during sedation. Midazolamealfentanil pairing was most synergistic, followed by propofolealfentanil and midazolamepropofol pairings. The Minto model compared with our NLMAZ model reported a decrease in U 50 of 44% vs 24% for midazolamealfentanil, 35% vs 13.8% for midazolamepropofol and 16% vs 17% for propofolealfentanil. Both studies identified midazolam and alfentanil as the strongest synergistic pairs but the NMLAZ model differs by identifying midazolamepropofol as the weakest interaction compared with propofolealfentanil in the Minto model.
Findings from another study support greatest synergy with the midazolamealfentanil pairing in the Minto and NLMAZ models but found little synergistic effect when a third drug was simultaneously given.
14 Differences in drug behaviour between the Minto and our NLMAZ model may be a result of the choice of endpoint. We used painful and tactile stimuli (MOAA/S<2) while Minto used verbal stimuli. We suggest that the analgesic requirements will be greater at MOAA/S<2, which may explain the stronger propofolealfentanil interaction in our study. Our model suggests a limited role for alfentanil in sedation. The large C 50a shows an inability to achieve MOAA/S<2 and Concentrationeeffect curve with patient concentration sets (red filled circles). We have plotted with fixed alfentanil fraction at 0.1 and progressive fractional changes (at 0.1 intervals) for midazolam and propofol. A 10% error margin is allowed for patient's drug concentration fraction to be plotted. The red dotted line is the drop-line from 50% probability of LOR, showing the concentration required for both midazolam and propofol to reach this probability. LOR, loss of response.
identified a modelling limitation. Opioids alone do not produce reliable hypnosis and therefore measuring end effect using hypnosis can produced results that are not clinically meaningful. Our results are indicative of the inability of alfentanil to produce hypnosis. Thus, the alfentanil fraction in our data rarely exceeded 0.12 because the large C 50a require doses that exceed those used in actual clinical practice. C 50m and C 50p are comparable with previous studies. Synergism between drug pairs was attenuated with an increasing concentration of the third drug. An intuitive explanation is that a significant portion of synergism (U 50 ) is removed from the visible isoboles in Figure 4 . Under these conditions the U 50 should remain in the synergistic range (<0.9) across the isoboles. Rather, we observed an increase in U 50 as the third drug concentration increased.
U 50 exceeded 0.9 when either drug approached 72e76% of its C 50 value, or 0.8e0.85 fraction. Shafer pointed out that additivity is a common interpretation when the fraction of a drug exceeds 0.9 in a two-drug model. This made synergy detection difficult. 20 The exact proportion needed to replication this observation in a three-drug model is unknown but it is probably variable as a result of its complex nature. In our NLMAZ model, we concluded any drug concentration beyond 72e76% C 50 value express additive effects for 50% probability of LOR. The 76%, 76%, and 72% C 50 value of alfentanil, midazolam, and propofol would be 480 ng ml À1 , 39 ng ml À1 , and 1.9 mg ml
À1
, respectively. Our model predicts that sedative effects of drugs given below these values are maximally enhanced by synergism.
We analysed the RD concentration sets separately to better understand the aetiology of RD. These effects are influenced by drug synergism. 33, 34 The number of RD observations in this study was insufficient to construct a complete response surface. Fraction transformation of the drugs is a core concept of the model. This approach also estimates the combined effect of the given drugs and we reason this approach better reflects clinical practice. Alfentanil may have the largest role in RD. We compared our findings to those of LaPierre and colleagues 34 who also used RD as an outcome measure. The reported C 50p and C 50,remifentanil was 7.0 mg ml À1 and 4.1 ng ml À1 . An equipotent alfentanil concentration was calculated using a potency ratio for alfentanil: remifentanil of 0.0625:1.2, 35 and the converted C 50a for RD is 78.72 ng ml À1 . The C 50a and concentration for RD were within our patient's range. In addition, the threshold of C 50p for RD was beyond our highest propofol concentration. 34 Our data did not identify midazolam as an important contributing cause of RD. This is supported by a study in which steady state midazolam concentration of 150 ng ml À1 caused no RD at MOAA/S score of 2e3. 36 In another study, a single 0.075 mg kg À1 dose of midazolam for endoscopic sedation did not cause RD. 18 This was above the maximal single dose (0.056 mg kg À1 ) administered in our study.
These findings support our conclusion that alfentanil was the principle cause of clinically significant RD during sedation. We therefore constructed an alfentanil plane drawn at 0.12 drug fraction (Fig. 6) to represent an increased risk of RD. The estimate of 0.12 alfentanil drug fraction was supported by our observation that the plane covered 90.3% of the data sets below it and all RD events were above the plane, over the LOR probability >0.5 region. The plane therefore serves as a visual aid to inform care providers of an increasing risk for respiratory depression.
There are limitations to our study. The use of patients instead of volunteers limited our ability to obtain equally distributed data including the extreme ranges of administered drugs. This caused some clustering of available concentration sets. Even though we could not administer drugs in the extreme ranges, our findings reflect the clinical as opposed to experimental conditions. We also could not discern if the number of patients needed to build a reliably performing three-drug model is the same as a dual-drug model. 16 Further studies are warranted to identify an efficient trial design in three-drug models. There were few cases of RD in our study. We therefore need additional data to build a model that addresses sedation safety. This could modify our threshold for safety monitoring.
Overfitting is an issue with complex models. Overparameterisation can cause overfitting and poor performance in the validation data set. Inclusion of a validation group in this study provided evidence of acceptable model performance. Many parameters are near zero (the g values).
Fixing these values to zero may have little impact on the final results and are useful to down-parameterise the model. However, our result may only be suitable for a specific patient group and effect-measure. The process of down-parameterisation should be rigorous and performed under stringent conditions. We plan to systematically reduce the parameters in future studies.
In addition, the rapid turnover of endoscopic cases prevented us from reaching steady-state concentrations. This interferes with the precise titration of drugs, such as midazolam. This unfavourable experimental condition, however, reflects clinical practice and provides observations that are more meaningful for patient care.
In summary, we studied interactions between midazolam, alfentanil, and propofol Ce under clinical conditions using the NLMAZ model. The ability of the NLMAZ model to predict the interaction between triple drug combinations is supported by similar observations in the literature and the model's ability to predict LOR across clinical dose ranges in a separate sample of patients used specifically for validation. Our model sets a RD warning plane to avoid over sedation during LOR. Further validation with larger number of patients is warranted to confirm clinical utility of the model.
